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Abstract
Ventilator-associated pneumonia (VAP) is a new (nosocomial)
lower respiratory tract infection diagnosed in mechanically
ventilated patients 48 or more hours after intubation. There is no
gold standard for establishing the diagnosis and its pathogenesis
is iatrogenic and multifactorial. Gastro-oesophageal reflux is
common in mechanically ventilated children, but its role in VAP
remains speculative. VAP is associated with increased mortality
and morbidity, prolonged duration of ventilation and hospital stay,
and escalated costs of hospitalisation. VAP ‘bundles’ are
championed as the antidote.
Ventilator-associated pneumonia (VAP) is defined as a new
(nosocomial) lower respiratory tract infection diagnosed in
mechanically ventilated patients ≥48 hours (‘early-onset’
VAP) or ≥4 days (‘late-onset’ VAP) after intubation [1-5].
Management of early-onset and late-onset VAP may differ as
the causative factors and likely pathogens will influence
treatment strategies, such as antimicrobial therapy [2,3,5].
VAP is associated with increased mortality and morbidity,
prolonged duration of ventilation and hospital stay, and
escalated costs of hospitalisation [2,3,5-9]. In resource-rich
countries VAP is reported to be the second most common
nosocomial/hospital-acquired infection in pediatric and
neonatal intensive care units, with incidences ranging from 3
to 30% and VAP-attributable mortality rates up to 20%
[5,7,9]. The potential devastating impact of VAP is
emphasized by the study of Abdel Gawad and colleagues [1]
where a 50% incidence of VAP and 70% mortality with VAP
means that more than 80% of all the deaths in their unit were
due to hospital-acquired infection/VAP.
Defining VAP is the easy aspect, making the correct
diagnosis (let alone confirmation) becomes more challenging,
and establishing universally accepted criteria is a distant goal.
There is no gold standard. The Clinical Pulmonary Infection
Score (CPIS), utilized in the study by Abdel Gawad and
colleagues, is based on five clinical parameters - fever,
leucocytosis, purulence of secretions, oxygenation, extent of
radiographic infiltrates - and strengthened by cultures from
the lower respiratory tract (most often broncho-alveolar
lavage (BAL)) [10]. It suffers from poor inter-rater agreement
and retrograde influence from positive BAL results [11]. The
current reference standard (read ‘gold standard’) comprises
the clinical criteria for the diagnosis of VAP established by
the National Nosocomial Infection Surveillance (NNIS) system
of the Centers for Disease Control and Prevention (CDC),
which incorporate age-specific criteria [4]. They do not
require microbiological confirmation to diagnose pneumonia.
The CDC/NNIS criteria also suffer from inter-rater inconsis-
tency. Additionally, the recurrent question as to whether
positive BAL cultures reflect true infection or merely bacterial
colonization lingers. Moreover, many studies show weak
concordance between designated diagnostic criteria and
clinical diagnosis of VAP by ‘experts’ [5,7,8,12]. To further
muddy the waters, the ‘Big-Brother’ effect of mandatory
reporting of health care-associated infections in many countries
and penalties for underperformance complicates inter-
institutional comparisons by blunting diagnostic accuracy.
The pathogenesis of VAP is iatrogenic and multifactorial, with
major factors being: the endotracheal tube facilitating
microbial access to the lung and providing a nidus for growth
of biofilm-encased bacteria; micro-aspiration from oropharynx
or gastrointestinal tract; extension of existing micro-infection
(foci of localized micro-infection causing local bronchiolitis
without clinically relevant pneumonia that proceed to develop
into macro-bronchopneumonia); blood-borne transmission
from other sites; and inhalation/instillation of contaminants
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(for example, aerosols or cross-infected suction catheters)
[2,5,8,9,13]. Endogenous community-acquired pathogens
are generally responsible for early-onset and nosocomial
microbes residing in oropharyngeal or gastric contents for
late-onset VAP.
Abdel Gawad and colleagues [1] confirmed that gastro-oeso-
phageal reflux (GER) is common in mechanically ventilated
children [14]. The authors demonstrated reflux of alkaline or
acidic gastric fluids into the lower half of the oesophagus (pH
probe positioned 5 cm above the gastro-oesophageal
sphincter), but have not demonstrated gastric fluid in the
oropharynx or bronchial tree. Neither have they shown
changes in pH or gastric pepsin in the bronchial tree to
support their inference of gastro-pulmonary spill-over. A high
incidence of GER in both VAP and non-VAP patients, along
with small sample size, restricts the association of GER with
VAP to speculation. A lack of reported data concerning
surveillance cultures from the oropharynx and gastro-intes-
tinal tract also curtail support for a gastro-pulmonary route of
VAP infection. The paucity of these data additionally prevents
understanding whether the VAP is endogenous or exogenous
in origin. The low incidence of BAL culture identifying
Staphylococcus aureus would suggest a low rate of
endogenous VAP. The high incidence of Klebsiella and
Acinetobacter (especially if multi-resistant organisms) implies
exogenous infection transmission (EXIT) and/or late-onset
VAP. Surprisingly, no polymicrobial cultures were reported.
Polymicrobial cultures are well-described in other studies
[5,6,13].
The most compelling data are the association of acidic reflux
with VAP and especially death [1]. This finding is directly
contrary to the concept that the acidification of gastric
contents inhibits colonization with potentially pathogenic
bacteria [5,15]. If we are to believe that acidic reflux led to
gastro-pulmonary acidic rain-out, what were the mechanisms
that led to death? Hypotheses include: bronchial mucosal
and/or lung parenchymal damage by acid and pepsin;
neutralisation of pulmonary macrophages by gastric acid rain;
enhanced bacterial colonization of denuded aerodigestive
tract surfaces by potential pathogens.
Perhaps acidic GER reflects worsening disease severity and
is thereby related to death. Possibly there is no pulmonary
impact from presumed gastric acid rain-out, and most likely
EXIT is the key factor with cross-contamination of intubated
patients from an external (to the patient) multi-resistant
source. Certainly the high VAP incidence of 50% and
accompanying mortality of 70% reported by Abdel Gawad
and colleagues [1] is troubling. Even if it is a matter of death
with VAP rather than death from VAP, the answer to this
unit’s problem must lie with the introduction of VAP
prevention strategies or ‘VAP bundles’ [5,8,9], concentrating
on the basic modifiable risk factors rather than medicinal
options and certainly not escalating antibiotic sophistication.
VAP prevention strategies concentrate on education,
minimising invasive mechanical ventilation and reducing
airway contamination from endogenous (oropharynx, gastric,
and sputum retention) and exogenous sources (EXIT). Abdel
Gawad and colleagues reiterate the brutal reality that the
Grim Reaper remains a close friend of VAP.
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